The full US Senate yesterday confirmed the nomination of Alex Azar as Secretary of the US Health and Human Services Department.
The Senate voted 55-43 on Wednesday to confirm Mr Azar’s nomination. He had until early last year served as president of pharmaceutical major Eli Lilly (NYSE: LLY) USA, having joined the company in 2007. He will serve in the post vacated by Dr Tom Price, who resigned last September amid controversy over his use of private and expensive charter jets for official travel.
In the HHS role, Mr Azar will oversee the Food and Drug Administration as well as Medicare and Medicaid, which together spend hundreds of billions of dollars each year on prescription medications.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze